Intake of St John's wort improves the glucose tolerance in healthy subjects who ingest metformin compared with metformin alone

British Journal of Clinical Pharmacology

Volumn 79, Issue 2, 2015, Pages 298-306

  Stage, Tore Bjerregaard ^a   Pedersen, Rasmus Steen ^a   Damkier, Per ^a,b   Christensen, Mette Marie Hougaard ^a   Feddersen, Søren ^b   Larsen, John Teilmann ^c   Højlund, Kurt ^b   Brøsen, Kim ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c Mental Health Services in the Region of Southern Denmark   (Denmark)

Author keywords

drug herb interaction; metformin; pharmacodynamics; pharmacokinetics; St John's wort

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; C PEPTIDE; CREATININE; GLUCOSE; HEMOGLOBIN A1C; HYPERICUM PERFORATUM EXTRACT; MESSENGER RNA; METFORMIN; ORGANIC CATION TRANSPORTER 1; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; INSULIN; PLANT EXTRACT;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION AT STEADY-STATE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSSOVER PROCEDURE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HYPERICUM PERFORATUM; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN RESPONSE; INSULIN SENSITIVITY; LIMIT OF QUANTITATION; MALE; NORMAL HUMAN; OPEN STUDY; ORAL GLUCOSE TOLERANCE TEST; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RENAL CLEARANCE; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; CHEMISTRY; CONTROLLED CLINICAL TRIAL; DRUG EFFECTS; DRUG INTERACTION; GLUCOSE TOLERANCE TEST; HYPERICUM; SECRETION (PROCESS); YOUNG ADULT;

ADULT; ANTIDEPRESSIVE AGENTS; BLOOD GLUCOSE; CROSS-OVER STUDIES; DRUG INTERACTIONS; GLUCOSE TOLERANCE TEST; HUMANS; HYPERICUM; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; PLANT EXTRACTS; YOUNG ADULT;

EID: 84941142541     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12510     Document Type: Article

References (40)

1. WHO. Diabetes. In, edcentre WM: World Health Organization, 2012.
2. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854-865.
3. Hermann LS, Schersten B, Bitzen PO, Kjellstrom T, Lindgarde F, Melander A,. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care 1994; 17: 1100-1109.
4. Madiraju AK, Erion DM, Rahimi Y, Zhang XM, Braddock DT, Albright RA, Prigaro BJ, Wood JL, Bhanot S, MacDonald MJ, Jurczak MJ, Camporez JP, Lee HY, Cline GW, Samuel VT, Kibbey RG, Shulman GI,. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 2014; 510: 542-546.
5. Pentikainen PJ, Neuvonen PJ, Penttila A,. Pharmacokinetics of metformin after intravenous and oral administration to man. Eur J Clin Pharmacol 1979; 16: 195-202.
6. Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, Furlong TJ, Greenfield JR, Greenup LC, Kirkpatrick CM, Ray JE, Timmins P, Williams KM,. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 2011; 50: 81-98.
7. Takane H, Shikata E, Otsubo K, Higuchi S, Ieiri I,. Polymorphism in human organic cation transporters and metformin action. Pharmacogenomics 2008; 9: 415-422.
8. Chen L, Pawlikowski B, Schlessinger A, More SS, Stryke D, Johns SJ, Portman MA, Chen E, Ferrin TE, Sali A, Giacomini KM,. Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin. Pharmacogenet Genomics 2010; 20: 687-699.
9. Nies AT, Koepsell H, Winter S, Burk O, Klein K, Kerb R, Zanger UM, Keppler D, Schwab M, Schaeffeler E,. Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology 2009; 50: 1227-1240.
10. Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, Ianculescu AG, Yue L, Lo JC, Burchard EG, Brett CM, Giacomini KM,. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007; 117: 1422-1431.
11. Wright SH,. Role of organic cation transporters in the renal handling of therapeutic agents and xenobiotics. Toxicol Appl Pharmacol 2005; 204: 309-319.
12. Konig J, Zolk O, Singer K, Hoffmann C, Fromm MF,. Double-transfected MDCK cells expressing human OCT1/MATE1 or OCT2/MATE1: determinants of uptake and transcellular translocation of organic cations. Br J Pharmacol 2011; 163: 546-555.
13. Sato T, Masuda S, Yonezawa A, Tanihara Y, Katsura T, Inui K,. Transcellular transport of organic cations in double-transfected MDCK cells expressing human organic cation transporters hOCT1/hMATE1 and hOCT2/hMATE1. Biochem Pharmacol 2008; 76: 894-903.
14. +/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol 2006; 17: 2127-2135.
15. Rahimi R, Abdollahi M,. An update on the ability of St. John's wort to affect the metabolism of other drugs. Expert Opin Drug Metab Toxicol 2012; 8: 691-708.
16. Maeda T, Oyabu M, Yotsumoto T, Higashi R, Nagata K, Yamazoe Y, Tamai I,. Effect of pregnane X receptor ligand on pharmacokinetics of substrates of organic cation transporter Oct1 in rats. Drug Metab Dispos 2007; 35: 1580-1586.
17. Mueller SC, Uehleke B, Woehling H, Petzsch M, Majcher-Peszynska J, Hehl EM, Sievers H, Frank B, Riethling AK, Drewelow B,. Effect of St John's wort dose and preparations on the pharmacokinetics of digoxin. Clin Pharmacol Ther 2004; 75: 546-557.
18. Tannergren C, Engman H, Knutson L, Hedeland M, Bondesson U, Lennernas H,. St John's wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism. Clin Pharmacol Ther 2004; 75: 298-309.
19. Zhou S, Chan E, Pan SQ, Huang M, Lee EJ,. Pharmacokinetic interactions of drugs with St John's wort. J Psychopharmacol 2004; 18: 262-276.
20. Bauer S, Stormer E, Johne A, Kruger H, Budde K, Neumayer HH, Roots I, Mai I,. Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients. Br J Clin Pharmacol 2003; 55: 203-211.
21. Cho SK, Yoon JS, Lee MG, Lee DH, Lim LA, Park K, Park MS, Chung JY,. Rifampin enhances the glucose-lowering effect of metformin and increases OCT1 mRNA levels in healthy participants. Clin Pharmacol Ther 2011; 89: 416-421.
22. Knol MJ, Twisk JW, Beekman AT, Heine RJ, Snoek FJ, Pouwer F,. Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis. Diabetologia 2006; 49: 837-845.
23. Egede LE,. Major depression in individuals with chronic medical disorders: prevalence, correlates and association with health resource utilization, lost productivity and functional disability. Gen Hosp Psychiatry 2007; 29: 409-416.
24. Pan A, Lucas M, Sun Q, van Dam RM, Franco OH, Manson JE, Willett WC, Ascherio A, Hu FB,. Bidirectional association between depression and type 2 diabetes mellitus in women. Arch Intern Med 2010; 170: 1884-1891.
25. Tzvetkov MV, Vormfelde SV, Balen D, Meineke I, Schmidt T, Sehrt D, Sabolic I, Koepsell H, Brockmoller J,. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther 2009; 86: 299-306.
26. Christensen MM, Brasch-Andersen C, Green H, Nielsen F, Damkier P, Beck-Nielsen H, Brosen K,. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genomics 2011; 21: 837-850.
27. Shu Y, Brown C, Castro RA, Shi RJ, Lin ET, Owen RP, Sheardown SA, Yue L, Burchard EG, Brett CM, Giacomini KM,. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther 2008; 83: 273-280.
28. Song IS, Shin HJ, Shim EJ, Jung IS, Kim WY, Shon JH, Shin JG,. Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Clin Pharmacol Ther 2008; 84: 559-562.
29. Wang ZJ, Yin OQ, Tomlinson B, Chow MS,. OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet Genomics 2008; 18: 637-645.
30. Pedersen RS, Christensen MM, Brosen K,. Linkage disequilibrium between the CYP2C19∗17 allele and other clinically important CYP2C allelic variants in a healthy Scandinavian population. Eur J Clin Pharmacol 2012; 68: 1463-1464.
31. Nielsen F, Christensen MM, Brøsen K,. Quantitation of metformin in human plasma and urine by hydrophilic interaction liquid chromatography and application to a pharmacokinetic study. Ther Drug Monit 2014; 36: 211-217.
32. Hellemans J, Mortier G, De Paepe A, Speleman F, Vandesompele J,. qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol 2007; 8: R19.
33. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F,. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3: RESEARCH0034.
34. Hansen T, Drivsholm T, Urhammer SA, Palacios RT, Vølund A, Borch-Johnsen K, Pedersen O,. The BIGTT test: a novel test for simultaneous measurement of pancreatic β-cell function, insulin sensitivity, and glucose tolerance. Diabetes Care 2007; 30: 257-262.
35. Deuschle M,. Effects of antidepressants on glucose metabolism and diabetes mellitus type 2 in adults. Curr Opin Psychiatry 2013; 26: 60-65.
36. Rysa J, Buler M, Savolainen MJ, Ruskoaho H, Hakkola J, Hukkanen J,. Pregnane X receptor agonists impair postprandial glucose tolerance. Clin Pharmacol Ther 2013; 93: 556-563.
37. Novelli M, Beffy P, Menegazzi M, De Tata V, Martino L, Sgarbossa A, Porozov S, Pippa A, Masini M, Marchetti P, Masiello P,. St. John's wort extract and hyperforin protect rat and human pancreatic islets against cytokine toxicity. Acta Diabetol 2014; 51: 113-121.
38. Menegazzi M, Novelli M, Beffy P, D'Aleo V, Tedeschi E, Lupi R, Zoratti E, Marchetti P, Suzuki H, Masiello P,. Protective effects of St. John's wort extract and its component hyperforin against cytokine-induced cytotoxicity in a pancreatic β-cell line. Int J Biochem Cell Biol 2008; 40: 1509-1521.
39. Hukkanen J, Hakkola J, Rysä J,. Pregnane X receptor (PXR)-a contributor to the diabetes epidemic? Drug Metabol Drug Interact 2014; 29: 3-15.
40. Krausova L, Stejskalova L, Wang H, Vrzal R, Dvorak Z, Mani S, Pavek P,. Metformin suppresses pregnane X receptor (PXR)-regulated transactivation of CYP3A4 gene. Biochem Pharmacol 2011; 82: 1771-1780.